Literature DB >> 15842653

Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.

Claire Harrison1.   

Abstract

The myeloproliferative diseases (MPDs) present several therapeutic challenges in patients of childbearing potential. The most extensive literature exists for patients with essential thrombocythaemia, with over 200 pregnancies reported in retrospective case series. Yet there is conflicting data in relation to predicting pregnancy outcome and optimal management strategy. Pregnancy is less frequently reported for polycythaemia vera and myelofibrosis. There is a need for collaboration to further our knowledge in this field. Here, the literature is reviewed in detail and experience of different therapeutic strategies in pregnancy discussed. There is increasing understanding about the pathogenesis of placental dysfunction in inherited thrombophilia and antiphospholipid antibody syndrome pregnancy outcomes in these conditions parallel those reported for MPDs. Furthermore several large studies have influenced pregnancy management in these conditions and, whilst not directly applicable to MPDs, this data have potential to inform treatment protocols. This data are reviewed and a personal management strategy for pregnancy in MPD proposed.

Entities:  

Mesh:

Year:  2005        PMID: 15842653     DOI: 10.1111/j.1365-2141.2005.05400.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.

Authors:  Elisa Rumi; Irene Bertozzi; Ilaria C Casetti; Elisa Roncoroni; Chiara Cavalloni; Marta Bellini; Emanuela Sant'Antonio; Manuel Gotti; Virginia V Ferretti; Chiara Milanesi; Edoardo Peroni; Daniela Pietra; Cesare Astori; Maria Luigia Randi; Mario Cazzola
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

Review 2.  Special issues in myeloproliferative neoplasms.

Authors:  Tiziano Barbui; Guido Finazzi
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

Review 3.  Polycythemia Vera Management and Challenges in the Community Health Setting.

Authors:  Aaron T Gerds; Kim-Hien Dao
Journal:  Oncology       Date:  2017-01-18       Impact factor: 2.935

Review 4.  Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review.

Authors:  Kazuya Sakai; Akane Ueda; Masaaki Hasegawa; Yasunori Ueda
Journal:  Int J Hematol       Date:  2017-12-30       Impact factor: 2.490

Review 5.  Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Authors:  Elisabeth I Penninga; Ole W Bjerrum
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety.

Authors:  Lukas Schrickel; Florian H Heidel; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Andreas Hochhaus; Martin Griesshammer; Kai Wille
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-02       Impact factor: 4.553

7.  Chronic myeloproliferative neoplasms: a collaborative approach.

Authors:  Lisa Pieri; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-06-21       Impact factor: 2.576

8.  Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature.

Authors:  Spyridon Arampatzis; Ioannis Stefanidis; Vassilios Lakiopoulos; Luigi Raio; Daniel Surbek; Markus G Mohaupt
Journal:  Thromb J       Date:  2010-06-17

9.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

Review 10.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.